Selective Extirpation of Tattooed Lymph Node in Combination with Sentinel Lymph Node Biopsy in the Management of Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy

被引:2
|
作者
Dostalek, Lukas
Cerny, Andrej
Saskova, Petra
Pavlista, David [1 ,2 ]
机构
[1] Charles Univ Prague, Gynecol Oncol Ctr, Dept Obstet & Gynecol, Fac Med 1, Apolinarska 18, CZ-12800 Prague 2, Czech Republic
[2] Gen Univ Hosp Prague, Apolinarska 18, CZ-12800 Prague 2, Czech Republic
关键词
Breast cancer; Axilla; Carbon; Neoadjuvant chemotherapy; Sentinel lymph node; CHEMOTHERAPY; SURGERY; MULTICENTER; AXILLA; IMPACT; SEEDS;
D O I
10.1159/000514266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Axillary dissection has little diagnostic and therapeutic benefit in node-positive breast cancer patients in whom axillary disease has been completely eradicated after neoadjuvant chemotherapy (ypN0). We sought to assess the efficacy of an algorithm used for the identification of the ypN0 patient consisting of intraoperative evaluation of sentinel and tattooed (initially positive) lymph nodes. Methods: Included were T1 and T2 breast cancer patients with 1-3 positive axillary lymph nodes marked with carbon who were referred for neoadjuvant chemotherapy followed by a surgery. Axillary dissection was performed only in the patients with residual axillary disease after neoadjuvant chemotherapy on ultrasound or with metastases described in the sentinel or tattooed lymph nodes either intraoperatively or in the final histology. Results: Out of 62 initially included node-positive patients, 15 (24%) were spared axillary dissection. The detection rate of tattooed lymph nodes after neoadjuvant chemotherapy was 81%. The ypN0 patients were identified with 91% sensitivity and 38% specificity using ultrasound and intraoperative assessment of both sentinel and tattooed lymph node according to the final histology. Discussion/Conclusion: Lymph node marking with carbon dye is a useful and cost-effective method, which can be successfully implemented in order to reduce the number of patients undergoing axillary dissection. Low specificity of the presented algorithm was caused mostly by the overestimation of residual axillary disease on ultrasound.
引用
收藏
页码:623 / 629
页数:7
相关论文
共 50 条
  • [31] Breast conservation and sentinel lymph node biopsy after neoadjuvant systemic therapy
    Veronesi, R.
    Rodriguez, J.
    [J]. BREAST, 2009, 18 : S11 - S12
  • [32] Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary Lymph Node Dissection for Node-Positive Breast Cancer
    Bilimoria, Karl Y.
    Bentrem, David J.
    Hansen, Nora M.
    Bethke, Kevin P.
    Rademaker, Alfred W.
    Ko, Clifford Y.
    Winchester, David P.
    Winchester, David J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2946 - 2953
  • [33] Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
    Piltin, Mara A.
    Hoskin, Tanya L.
    Day, Courtney N.
    Davis, John, Jr.
    Boughey, Judy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (12) : 4795 - 4801
  • [34] Sentinel lymph node biopsy after neoadjuvant chemotherapy for patients with clinically node-positive breast cancer: A single institution retrospective evaluation
    Gallant, E.
    Ewing, C.
    Wong, J.
    Esserman, L.
    Alvarado, M.
    [J]. CANCER RESEARCH, 2016, 76
  • [35] The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer
    Cavalcante, Francisco Pimentel
    Zerwes, Felipe Pereira
    Souza, Alessandra Borba Anton
    Ziegelmann, Patricia Klarmann
    Alcantara, Ryane
    Cardoso, Amanda
    Mattar, Andre
    Millen, Eduardo Camargo
    Frasson, Antonio Luiz
    [J]. EJSO, 2024, 50 (03):
  • [36] Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis
    Choi, H. J.
    Jung, S. M.
    Ryu, J. M.
    Kim, I.
    Nam, S. J.
    Kim, S. W.
    Yu, J.
    Lee, S. K.
    Lee, J. E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [37] Blue Dye-Only for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Initially Node-positive Breast Cancer
    Cavalcante, Francisco Pimentel
    Zerwes, Felipe
    Souza, Alessandra
    Ziegelmann, Patricia
    Alcantara, Ryane
    Cardoso, Amanda
    Mattar, Andre
    Millen, Eduardo
    Frasson, Antonio
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [38] A Predictive Model for Nonsentinel Node Status after Sentinel Lymph Node Biopsy in Sentinel Lymph Node-Positive Chinese Women with Early Breast Cancer
    He, Lifang
    Liang, Peide
    Zeng, Huancheng
    Huang, Guangsheng
    Wu, Jundong
    Zhang, Yiwen
    Cui, Yukun
    Huang, Wenhe
    [J]. JOURNAL OF ONCOLOGY, 2022, 2022
  • [39] Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
    Mara A. Piltin
    Tanya L. Hoskin
    Courtney N. Day
    John Davis
    Judy C. Boughey
    [J]. Annals of Surgical Oncology, 2020, 27 : 4795 - 4801
  • [40] Sentinel lymph node biopsy for breast cancer patients after neoadjuvant endocrine therapy
    Tozuka, K.
    Matsumoto, H.
    Kurosumi, M.
    Hayashi, Y.
    Kubo, K.
    Kurozumi, S.
    Inoue, K.
    Nagai, S.
    Horiguchi, J.
    Takeyoshi, I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S134 - S134